Luxury jabs: The cost of immunity in a two-tiered childhood

Younis, Abdel Rahman, Mostafa, Leen are children between eight months and four years old. Egypt’s Child Law of 1996 mandates that they receive equal healthcare, and the Ministry of Health guarantees them access to a vaccination schedule running from birth through 18 months of age. But alongside this mandatory schedule exists a parallel one: a set of supplemental, unsubsidized vaccines that promise a better standard of health protection; available only to those who can pay for it.

The supplemental schedule covers seven vaccines, among them Rotarix, which protects children against gastroenteritis and dehydration; the pneumococcal vaccine; Hepatitis A; and the HPV vaccine, administered to adolescents and protective against certain cancers.

All are recommended by the World Health Organization and Egypt’s own Ministry of Health, and the majority of Arab countries have incorporated them into their mandatory immunization schedules. Most low-income African countries have similarly expanded access to them, backed by the Global Alliance for Vaccines and Immunization (GAVI).

Though these vaccines are technically available in Egypt, through VacSera centers, major pharmacies, and private clinics, they remain out of reach for most families. A single dose, whose price rose by 40% last year, now runs between 700 and 3,700 pounds ($13–71). Since each vaccine requires two to three doses per health guidelines, those figures double or triple; bringing the full supplemental course to between 18,000 and 21,000 pounds ($350–400) in total, depending on which vaccines are selected.

The price variation does not reflect product quality; it reflects the range of options available for each vaccine, typically two or three formulations that differ in mechanism or the number of strains they cover.

A two-tiered system of protection

Riham Mohamed, 28, mother of two, was unmoved when her pediatrician explained the importance of these vaccines at her youngest son Abdel Rahman’s eight-month checkup. Her decision was already made.

“Nobody around us gave them to their kids. And I didn’t give them to my first son, so I’m not giving them to the second one. What really settled it was the price. I told the doctor: 700 pounds for one shot!” she explained to Al Manassa.

The level of health protection Riham’s children receive looks nothing like what’s available to Younis, eighteen months old, whose family handles him, in his mother Salma Badr’s own words, “with kid gloves.”

She explains: “Younis is my second child. There was a boy before him who died at 15 days old.” That loss is what drove her to give her only surviving child every supplemental vaccine on the list.

Salma can see the difference it’s made. “His condition is better than a lot of children around us. One time he got a severe cold and we had to do steam therapy sessions. Three of the doctors following his case all confirmed that without the pneumococcal vaccine, we could have been looking at pneumonia.”

The pneumococcal vaccine, one dose at approximately 700 pounds,  guards against pneumonia, meningitis, blood poisoning, and middle ear infections. By the end of 2024, it had been introduced in 163 countries, according to the WHO.

Maximum protection at minimum cost

Every time a new round of doses comes due, Doaa Mohamed, mother of three-year-old twins Leen and Mostafa, faces the same unforgiving math. “The month there’s a vaccination is always a tight month, on top of the cost of diapers and formula for two kids,” she tells Al Manassa.

Because both twins have a history of allergies, supplemental vaccines are, in her words, “a necessity, not a luxury.” Which means she compresses every other expense to make room for them. “Even if I have to cut back on my own food.”

Before she gave birth, Doaa researched every vaccine; its price, its benefits, its schedule. After delivery, she continued consulting with her pediatrician: “We were figuring out together how to get the highest level of protection for the lowest possible cost.”

That principle drove a series of strategic decisions. “For example, we chose the two-dose Rotarix formulation instead of the three-dose one. And after we missed the nine-month dose of Hepatitis A, we went straight to the one-year dose. The doctor said it wouldn’t make a significant difference.”

Doaa, who works as a freelance journalist, is currently racing against the calendar to secure the varicella (chickenpox) vaccine before summer. “That’s when the virus really flares up and devastates kids, plus I also need them in daycare. I have to come up with the price of the vaccine, at minimum 1,500 pounds per dose per child, so at least 3,000 pounds before summer, and then another round three months later for the second dose.”

Outside the capital: A near-total absence

Riham, Salma, and Doaa are unequal in their ability to afford supplemental vaccines. Yet, they are equal in one respect: these vaccines are at least physically accessible to all three, whether through private clinics or VacSera centers.

That basic access does not exist for most of the country. Cairo alone has 18 VacSera branches; Giza has 4; Alexandria has just one. A single branch in Kafr El-Sheikh serves the entire Delta region. Upper Egypt, home to millions, makes do with two branches in Beni Suef and Assiut, both opened within the past two years. Against that backdrop, the shock registered by Shaimaa Sayed, 30, from Sohag governorate, when she first heard that supplemental vaccines existed at all becomes entirely intelligible.

Shaimaa has three children. Every vaccination appointment meant climbing into a tuk-tuk from her village, Ninit Al-Gharbiya, to the neighboring village where the health office is located, because there was no health office in her own. That was the rhythm of her life until her husband announced they would be relocating to Shubra El-Kheima for work.

When her daughter Hajar turned two months old, Shaimaa carried her to the nearest health office in their new neighborhood. “That’s where I heard two mothers talking about vaccines other than the government ones,” she tells Al Manassa.

Shaimaa holds a degree in Arabic Literature. Yet like everyone in her orbit, she had been denied even the right to know these vaccines existed. “Nobody around me knew there were outside vaccines. Even the doctor I followed up with at the center never mentioned them.”

She wonders, now, what might have been different had she known sooner and whether it might have spared her middle child, Abdel Rahman, four years old, from the recurring pneumonia that lands him in the hospital every time he catches a cold.

“He got a severe cold at four months and it developed into pneumonia.” At the time, she had never heard of the pneumococcal vaccine. “If anyone had told me there was a vaccine that would keep us out of the hospital, I would have found a way to get it…even for money.”

That reasoning is one that Dr. Mohamed Ihab, a pediatrician in Sohag, fully endorses. He tells Al-Manassa that the long-term cost to the state of providing these vaccines for free would ultimately be far cheaper than “leaving children to get sick and need hospitalizations and treatment.”

Between Sohag and New Cairo

Dr. Ihab runs two clinics, one in Sohag, one in New Cairo, which gives him a direct comparative lens on awareness and uptake of supplemental vaccines across both settings. “In New Cairo, awareness is higher and the financial factor isn’t really a crisis,” he says.

In Sohag, the financial barrier remains the primary obstacle: “Over 20 years, there’s been real effort to educate families about supplemental vaccines, and the results show—but the effort is still short of what’s needed. There are still families that need education from zero.”

The disparity he observes between Cairo and Sohag is even starker in villages far from urban centers. “There are no supplemental vaccines in the villages, and in the cities they’re present at maybe 5%,” says pediatrician Dr. Osama Gouda, flatly.

With VacSera centers absent from most governorates, private clinics and major pharmacies become the default channel, and even that supply chain is unreliable. Dr. Ihab flags “supply problems” that doctors must actively work around when sourcing vaccines for their governorate.

“Sometimes the quantities coming into Egypt are limited. Some people know this and start stockpiling and selling on the black market. It happens in Cairo too, but the impact isn’t the same as in Sohag, because of how many VacSera branches there are.” The most recent vaccine to experience a critical shortage, he notes, was varicella “for three months before it became available again.”

This is why he advocates for a VacSera branch in Sohag. The Assiut branch, as its director Dr. Mohamed Mahmoud confirms to Al Manassa, “serves everyone from Minya to Aswan.”

Unanswered queries

Given the growing disparity in access, financial and geographic alike, and the mounting consensus around these vaccines’ importance, from pediatricians to the Ministry of Health’s own official platforms, the central question becomes: why aren’t supplemental vaccines incorporated into the national schedule, where equal access would be guaranteed?

In January, MP Mai Karam Jaber submitted a formal parliamentary inquiry to the Minister of Health regarding the exclusion of Rotarix and the pneumococcal vaccine from the free mandatory vaccination program for infants up to six months of age.

Dr. Hossam Abdel Ghaffar, the Ministry of Health spokesperson, attributes the exclusion to “public health priorities” namely the focus on “the most life-threatening diseases,” alongside the need to guarantee supply sustainability before any new vaccine is introduced into the mandatory schedule.

He explains to Al Manassa that any vaccine’s inclusion is subject to scientific evaluation by the National Immunization Committee, “according to precise criteria encompassing disease burden and economic feasibility.”

He draws a distinction between mandatory and supplemental vaccines: the former “aim to prevent diseases with the highest epidemiological burden and direct impact on public health, such as polio, measles, and diphtheria,” while the latter, though also important, “are incorporated according to specific health and economic priorities, including disease burden, vaccine cost, WHO recommendations, and the potential impact of their inclusion on system sustainability.”

He is emphatic that “the difference is not in medical importance, but in the priority of inclusion within a comprehensive, fully state-funded national program,” and frames the relevance of supplemental vaccines as tied to “epidemiological contexts and specific population groups.” Even while acknowledging their contribution to “reducing infection rates and hospital admissions,” he notes they “are still being evaluated based on local disease burden.”

Asked whether there is a concrete future plan to integrate these vaccines into the mandatory schedule, he confirms that immunization schedules “are reviewed periodically in light of epidemiological shifts and international recommendations,” and does not rule out that a 30% increase in the health budget for 2026/2027—announced the previous week by Finance Minister Ahmed Kouchouk—could afford “greater flexibility to consider adding new vaccines.” He adds the caveat: “But the decision remains tied to scientific assessment, not financing alone.”

The Ministry spokesperson characterizes Egypt’s vaccination program overall as “one of the most successful public health programs” in the country, one that “balances protecting citizens’ health with the sustainability of resources.”

A delegation from GAVI visited Egypt’s Ministry of Health on April 23rd “to discuss ways of strengthening joint cooperation in the vaccination system,” according to the Ministry’s official statement. GAVI is an international alliance of organizations and governments aimed at immunizing children in developing countries; the form its support takes varies by income level, with direct funding available to low-income countries, while middle-income countries like Egypt receive reduced direct support, limited at times to technical cooperation and knowledge transfer.

Al Manassa reached GAVI via email, where a spokesperson confirmed the recent visit included “discussions related to the potential introduction of the pneumococcal vaccine (PCV),” noting these remain “at an early stage.”

GAVI also clarified that its middle-income country support program has entered what it calls the “incentive phase,” in which the alliance focuses on helping these countries “sustainably introduce priority vaccines”: specifically the pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and HPV vaccine, with the possibility of future support for dengue and tuberculosis vaccines.

The alliance shared with Al Manassa a list of 36 countries, Egypt among them, currently in the incentive phase and eligible for GAVI support as of the beginning of this year.

Dr. Alaa Ghannam, head of the Right to Health program at the Egyptian Initiative for Personal Rights, affirms children’s entitlement to these vaccines as a rights matter, and proposes to Al-Manassa that health insurance absorb the cost “after the family brings a doctor’s note certifying their child’s need for the vaccine.”

Until that happens, or until GAVI support materializes, families are left to manage the cost of these vaccines on their own, navigating their household income against their children’s medical needs.